See more : Bond Resources Inc. (BJB.CN) Income Statement Analysis – Financial Results
Complete financial analysis of IO Biotech, Inc. (IOBT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IO Biotech, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Viaplay Group AB (publ) (VPLAY-A.ST) Income Statement Analysis – Financial Results
- RHÖN-KLINIKUM Aktiengesellschaft (RHK.SW) Income Statement Analysis – Financial Results
- Medicalsystem Biotechnology Co., Ltd. (300439.SZ) Income Statement Analysis – Financial Results
- New Times Energy Corporation Limited (0166.HK) Income Statement Analysis – Financial Results
- Tenaz Energy Corp. (TNZ.TO) Income Statement Analysis – Financial Results
IO Biotech, Inc. (IOBT)
About IO Biotech, Inc.
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 756.00K | 540.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -756.00K | -540.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 67.83M | 46.99M | 30.15M | 8.46M | 7.94M |
| General & Administrative | 23.61M | 24.44M | 11.08M | 1.68M | 1.98M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 23.61M | 24.44M | 11.08M | 1.68M | 1.98M |
| Other Expenses | 0.00 | 0.00 | -26.54M | -1.99M | -781.00K |
| Operating Expenses | 91.44M | 71.42M | 41.23M | 10.15M | 9.91M |
| Cost & Expenses | 91.44M | 71.42M | 41.23M | 10.15M | 9.91M |
| Interest Income | 5.88M | 1.41M | 361.00 | 26.00 | 6.00 |
| Interest Expense | 0.00 | 302.00K | 361.00K | 26.00K | 6.00K |
| Depreciation & Amortization | 215.00K | 540.00K | 2.00K | 10.15M | 9.91M |
| EBITDA | -91.44M | -69.34M | -67.45M | 0.00 | -824.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -91.44M | -71.42M | -41.23M | -10.15M | -9.91M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.21M | 1.24M | -26.58M | -1.90M | -830.00K |
| Income Before Tax | -85.23M | -70.19M | -67.81M | -12.04M | -10.74M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 852.00K | 1.27M | 68.00K | 26.00K | 6.00K |
| Net Income | -86.08M | -71.46M | -67.88M | -12.07M | -10.75M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.98 | -2.48 | -2.36 | -0.42 | -0.37 |
| EPS Diluted | -1.98 | -2.48 | -2.36 | -0.42 | -0.37 |
| Weighted Avg Shares Out | 43.54M | 28.82M | 28.82M | 28.82M | 28.82M |
| Weighted Avg Shares Out (Dil) | 43.54M | 28.82M | 28.82M | 28.82M | 28.82M |
Insider Buying: Taking a Controlling Stake in a Struggling Retailer?
The biggest insider trading news of the week may have been Amazon.com Inc. (NASDAQ: AMZN) founder Jeff Bezos shedding over $4 billion worth of the company's shares as he reportedly prepares to move to Florida to take advantage of the...
IO Biotech: A Phase 3 Company Getting No Respect
IO Biotech is an immunotherapy biotech in phase 3 trials. Past failures of IDO as a target cast a pall on their potential data readouts. Nevertheless, the cheap stock price and upcoming catalysts make this an interesting play.
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial
NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating therapeutic cancer vaccines based on its T-win® platform, announced today that the first patient has been dosed in its Phase...
IO Biotech Announces 2023 Third Quarter Results
Completed enrollment of 380 patients in pivotal Phase 3 trial of lead therapeutic cancer vaccine, IO102-IO103 in combination with KEYTRUDA® (pembrolizumab), in patients with advanced melanoma Presented encouraging preliminary data from Phase 2 basket trial of IO102-IO103 at the IASLC...
IO Biotech Appoints Helen Collins, MD, to its Board of Directors
NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating cancer vaccines based on its T-win® technology platform, announced the appointment of Helen Collins, MD, to its board of directors....
IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma
Trial expected to reach the primary endpoint of progression free survival in the second half of 2025 Per-protocol interim analysis expected in mid-2024 NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing...
IO Biotech Announces Participation in Upcoming Investor Conferences
NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced its participation in the upcoming investor conferences: Event: Jefferies London Healthcare...
IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating cancer vaccines based on its T-win® technology platform, today announced three poster presentations at the Society for Immunotherapy of Cancer's...
Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology (ESMO) Congress
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines, announced encouraging preliminary data from the company's Phase 2 basket trial of IO102-IO103 in combination with Merck's anti-PD-1...
IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting
NEW YORK, Oct. 03, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced three poster presentations at the Society for Immunotherapy of Cancer's 38th Annual...
Source: https://incomestatements.info
Category: Stock Reports